Moreover, considering the biological mechanism underlying PSMA-targeting radiopharmaceuticals uptake in HCC, PSMA-targeted PET/CT has excellent potential in the prediction and assessment of treatment response, but more prospective studies comparing its performances with CT and MRI in these settings are needed to evaluate its exact role as well as the correct timing of the functional imaging evaluation based on the type of treatment the patients were submitted to. Here, FOLH1 is linked to hepatocellular carcinoma.